MedTrace Logo

A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant

NCT04494061 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2022-10-21

No results posted yet for this study

Summary

Clinical study designed to collect blood for research purposes in patients after hematopoietic stem cell transplantation (HSCT) or in patients with a medical condition where the blood cells production is impaired. The blood samples will be used to study the role of Interferon gamma (IFNɣ) in graft failure or impairment of hematopoietic stem cell proliferation. The IFNɣ signature will be assessed by measuring primarily IFNɣ and C-X-C Motif Chemokine Ligand 9 (CXCL9).

Conditions

  • Graft Failure

Interventions

PROCEDURE

blood collection

Blood samples will be collected as per protocol defined schedule. There is no investigation drug in this study.

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • Cytel Inc.

    collaborator INDUSTRY

  • BioMérieux

    collaborator INDUSTRY

  • Swedish Orphan Biovitrum

    lead INDUSTRY

Principal Investigators

  • Regis Peffault de Latour, MD · Hôpital Saint Louis Paris

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-16
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • Belgium
  • France
  • Germany
  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04494061 on ClinicalTrials.gov